Epigenetic mechanisms in COPD: Implications for pathogenesis and drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 6, 2014, Pages 609-628

  Schamberger, Andrea C ^a   Mise, Nikica ^a   Meiners, Silke ^a   Eickelberg, Oliver ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CPC Institute of Lung Biology and Disease (ILBD) DZL   (Germany)

Author keywords

Biomarker; Chronic obstructive pulmonary disease; DNA methyltransferase inhibitors; DNA modification; Emphysema; Histone deacetylase activators; Polycomb

Indexed keywords

HISTONE DEACETYLASE; MICRORNA; POLYCOMB GROUP PROTEIN; UNTRANSLATED RNA; DNA; HISTONE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DEACETYLATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE SILENCING; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RISK FACTOR; ANIMAL; DRUG DESIGN; DRUG DEVELOPMENT; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; DNA; DRUG DESIGN; DRUG DISCOVERY; EPIGENESIS, GENETIC; HISTONES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; RNA, UNTRANSLATED;

EID: 84901251854     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.913020     Document Type: Review

References (148)

1. WHO. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. 2013. Available from: Http://www. goldcopd.org/uploads/users/files/ GOLD-Report-2013-Feb20.pdf [cited 13 January 2014]
2. WHO. Chronic obstructive pulmonary disease (COPD). 2013. Fact sheet N-315. Available from: Http:// www.who.int/mediacentre/factsheets/ fs315/en/ [cited 13 January 2014]
3. WHO. The global burden of disease: 2004 update. 2013. Available from: Http://www.who.int/healthinfo/ global-burden-disease/ GBD-report-2004update- full.pdf [cited 13 January 2014]
4. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007;370(9589):741-50 (Pubitemid 47321907
5. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet 2005;366(9500):1875-81 (Pubitemid 41690116
6. Lopez Varela MV, Montes de Oca M, Halbert R, et al. Comorbidities and health status in individuals with and without COPD in five latin american cities: The PLATINO study. Arch Bronconeumol 2013;49(11):468-74
7. WHO. World health statistics 2008. 2008. Available from: Http://www.who. int/whosis/whostat/EN-WHS08-Full.pdf [cited 11 September 2012]
8. WHO. Projections of mortality and causes of death, 2015 and 2030. Available from: Http://www.who.int/ entity/healthinfo/global-burden-disease/ GHE-DthGlobal-Proj-2015-2030.xls [cited 14 January 2014]
9. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: Systematic review and meta-Analysis. Eur Respir J 2006;28(3):523-32 (Pubitemid 44794666
10. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD?-Report from the obstructive lung disease in Northern Sweden studies. Respir Med 2003;97(2):115-22 (Pubitemid 36284990
11. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374(9691):733-43
12. Toren K, Jarvholm B. Occupational exposure to vapors, gases, dusts and fumes and mortality in relation to chronic obstructive pulmonary disease among Swedish construction workers-A longitudinal cohort study. Chest 2013. [Epub ahead of print]
13. Ezzati M, Hoorn SV, Lopez AD, et al. Comparative quantification of mortality and burden of disease attributable to selected risk factors. Chapter 4. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. Global burden of disease and risk factors. Oxford University Press and The World Bank, Washington, DC; 2006
14. Lopez Varela MV, Montes de Oca M, Halbert RJ, et al. Sex-related differences in COPD in five Latin American cities: The PLATINO study. Eur Respir J 2010;36(5):1034-41
15. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162(6):2152-8 (Pubitemid 32051679
16. Foreman MG, Zhang L, Murphy J, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med 2011;184(4):414-20
17. Gingo MR, Morris A, Crothers K. Human immunodeficiency virusassociated obstructive lung diseases. Clin Chest Med 2013;34(2):273-82
18. Lee CH, Lee MC, Lin HH, et al. Pulmonary tuberculosis and delay in anti-Tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One 2012;7(5):e37978
19. United Nations DoEaSA, Population Division. World Population Prospects: The 2012 Revision, Volume I: Comprehensive Tables ST/ESA/SER.A/ 336. 2013. Available from: Http://esa.un. org/wpp/Documentation/pdf/ WPP2012-Volume-I- Comprehensive-Tables.pdf [cited 18 February 2014]
20. United Nations DoEaSA, Population Division. World Population Prospects: The 2012 Revision, Volume II: Demographic Profiles. ST/ESA/SER.A/ 345. 2013. Available from: Http://esa.un. org/wpp/Documentation/pdf/ WPP2012-Volume-II- Demographic-Profiles.pdf [cited 18 February 2014]
21. Foreman MG, Campos M, Celedon JC. Genes and chronic obstructive pulmonary disease. Med Clin North Am 2012;96(4):699-711
22. Stoller JK, Aboussouan LS. Alpha1-Antitrypsin deficiency. Lancet 2005;365(9478):2225-36
23. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-59
24. Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012;122(8):2749-55
25. Schamberger AC, Mise N, Jia J, et al. Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by transforming growth factor-beta. Am J Respir Cell Mol Biol 2013. [Epub ahead of print]
26. Heijink IH, Brandenburg SM, Postma DS, van Oosterhout AJ. Cigarette smoke impairs airway epithelial barrier function and cell-cell contact recovery. Eur Respir J 2012;39(2):419-28
27. Russo VEA, Martienssen RA, Riggs AD. Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press; Plainview, NY; 1996
28. Puck JM, Willard HF. X inactivation in females with X-linked disease. N Engl J Med 1998;338(5):325-8 (Pubitemid 28065261
29. Talens RP, Christensen K, Putter H, et al. Epigenetic variation during the adult lifespan: Cross-sectional and longitudinal data on monozygotic twin pairs. Aging Cell 2012;11(4):694-703
30. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102(30):10604-9 (Pubitemid 41061601
31. Brix TH, Hegedus L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf) 2012;76(4):457-64
32. Runyon RS, Cachola LM, Rajeshuni N, et al. Asthma discordance in twins is linked to epigenetic modifications of T cells. PLoS One 2012;7(11):e48796
33. Givelber RJ, Couropmitree NN, Gottlieb DJ, et al. Segregation analysis of pulmonary function among families in the Framingham Study. Am J Respir Crit Care Med 1998;157(5 Pt 1):1445-51
34. Tager I, Tishler PV, Rosner B, et al. Studies of the familial aggregation of chronic bronchitis and obstructive airways disease. Int J Epidemiol 1978;7(1):55-62 (Pubitemid 8328482
35. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62(8):2370-7 (Pubitemid 34411720
36. Barnes PJ. Reduced histone deacetylase in COPD: Clinical implications. Chest 2006;129(1):151-5 (Pubitemid 43265256
37. Adcock IM, Tsaprouni L, Bhavsar P, Ito K. Epigenetic regulation of airway inflammation. Curr Opin Immunol 2007;19(6):694-700 (Pubitemid 350236802
38. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur Respir J 2005;25(3):552-63 (Pubitemid 40331188
39. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002;3(9):662-73 (Pubitemid 34984255
40. Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med 2012;185(4):373-81
41. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010;29(25):3650-64
42. Monick MM, Beach SR, Plume J, et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am J Med Genet B Neuropsychiatr Genet 2012;159B(2):141-51
43. Vucic EA, Chari R, Thu KL, et al. DNA methylation is globally disrupted and associated with expression changes in COPD small airways. Am J Respir Cell Mol Biol 2013. [Epub ahead of print]
44. Phillips JM, Goodman JI. Inhalation of cigarette smoke induces regions of altered DNA methylation (RAMs) in SENCAR mouse lung. Toxicology 2009;260(1-3):7-15
45. Breton CV, Byun HM, Wenten M, et al. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am J Respir Crit Care Med 2009;180(5):462-7
46. Hollams EM, de Klerk NH, Holt PG, Sly PD. Persistent effects of maternal smoking during pregnancy on lung function and asthma in adolescents. Am J Respir Crit Care Med 2014;189(4):401-7
47. Georgiou E, Valeri R, Tzimagiorgis G, et al. Aberrant p16 promoter methylation among Greek lung cancer patients and smokers: Correlation with smoking. Eur J Cancer Prev 2007;16(5):396-402 (Pubitemid 47549998
48. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet 2012;21(13):3073-82
49. Breitling LP, Yang R, Korn B, et al. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011;88(4):450-7
50. Siedlinski M, Klanderman B, Sandhaus RA, et al. Association of cigarette smoking and CRP levels with DNA methylation in alpha-1 antitrypsin deficiency. Epigenetics 2012;7(7):720-8
51. Lam HC, Cloonan SM, Bhashyam AR, et al. Histone deacetylase 6-mediated selective autophagy regulates COPDassociated cilia dysfunction. J Clin Invest 2013;123(12):5212-30
52. Liu H, Zhou Y, Boggs SE, et al. Cigarette smoke induces demethylation of prometastatic oncogene synucleingamma in lung cancer cells by downregulation of DNMT3B. Oncogene 2007;26(40):5900-10
53. Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung cancer 2007;55(2):205-13
54. Lin RK, Hsieh YS, Lin P, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010;120(2):521-32
55. Schwartz YB, Pirrotta V. A new world of Polycombs: Unexpected partnerships and emerging functions. Nat Rev Genet 2013;14(12):853-64
56. Simon JA, Kingston RE. Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 2013;49(5):808-24
57. Wolff EM, Liang G, Cortez CC, et al. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res 2008;68(15):6208-14
58. Xi S, Xu H, Shan J, et al. Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. J Clin Invest 2013;123(3):1241-61
59. Hascher A, Haase AK, Hebestreit K, et al. DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res 2014;20(4):814-26
60. Reed MD, Tellez CS, Grimes MJ, et al. Aerosolised 5-Azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br J Cancer 2013;109(7):1775-81
61. Syed DN, Afaq F, Kweon MH, et al. Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. Oncogene 2007;26(5):673-82 (Pubitemid 46204247
62. Chan KH, Ho SP, Yeung SC, et al. Chinese green tea ameliorates lung injury in cigarette smoke-exposed rats. Respir Med 2009;103(11):1746-54
63. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature 2013;502(7472):480-8
64. Grewal SI, Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003;301(5634):798-802 (Pubitemid 36962612
65. Feil R, Fraga MF. Epigenetics and the environment: Emerging patterns and implications. Nat Rev Genet 2011;13(2):97-109
66. Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J 2002;20(3):556-63
67. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174(1):41-50 (Pubitemid 43955243
68. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 2004;31(6):633-42 (Pubitemid 39587493
69. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006;291(1):L46-57
70. Rahman I, Gilmour PS, Jimenez LA, MacNee W. Oxidative stress and TNF-Alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: Potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem 2002;234-235(1-2):239-48 (Pubitemid 34777863
71. Sundar IK, Chung S, Hwang JW, et al. Mitogen-And stress-Activated kinase 1 (MSK1) regulates cigarette smokeinduced histone modifications on NF-kappaB-dependent genes. PLoS One 2012;7(2):e31378
72. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001;21(20):7065-77 (Pubitemid 32916079
73. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NFkappaB action regulated by reversible acetylation. Science 2001;293(5535):1653-7 (Pubitemid 32807844
74. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9(3):625-36 (Pubitemid 34273792
75. Chen Y, Huang P, Ai W, et al. Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD. J Inflamm 2012;9:10
76. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352(19):1967-76 (Pubitemid 40638367
77. Isajevs S, Taivans I, Svirina D, et al. Patterns of inflammatory responses in large and small airways in smokers with and without chronic obstructive pulmonary disease. Respiration 2011;81(5):362-71
78. Mizuno S, Yasuo M, Bogaard HJ, et al. Inhibition of histone deacetylase causes emphysema. Am J Physiol Lung Cell Mol Physiol 2011;300(3):L402-13
79. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kdelta restores glucocorticoid function in smokinginduced airway inflammation in mice. Am J Respir Crit Care Med 2009;179(7):542-8
80. Malhotra D, Thimmulappa RK, Mercado N, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest 2011;121(11):4289-302
81. To M, Takagi D, Akashi K, et al. Sputum plasminogen activator inhibitor-1 elevation by oxidative stress-dependent nuclear factor-kappaB activation in COPD. Chest 2013;144(2):515-21
82. Goven D, Boutten A, Lecon-Malas V, et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 2008;63(10):916-24
83. Malhotra D, Thimmulappa R, Navas-Acien A, et al. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 2008;178(6):592-604
84. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460(7255):587-91
85. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012;13(4):225-38
86. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-Associated diseases. Nat Rev Drug Discov 2008;7(10):841-53
87. Caito S, Rajendrasozhan S, Cook S, et al. SIRT1 is a redox-sensitive deacetylase that is post-Translationally modified by oxidants and carbonyl stress. FASEB J 2010;24(9):3145-59
88. Arunachalam G, Yao H, Sundar IK, et al. SIRT1 regulates oxidant-And cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem Biophys Res Commun 2010;393(1):66-72
89. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177(8):861-70 (Pubitemid 351600664
90. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004;23(12):2369-80 (Pubitemid 38954844
91. Isajevs S, Strazda G, Kopeika U, Taivans I. Different patterns of lung sirtuin expression in smokers with and without chronic obstructive pulmonary disease. Medicina (B Aires) 2012;48(10):552-7
92. Yao H, Chung S, Hwang JW, et al. SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest 2012;122(6):2032-45
93. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009;23(9):2810-19
94. Yao H, Hwang JW, Sundar IK, et al. SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol 2013;305(9):L615-24
95. Bakke PS, Zhu G, Gulsvik A, et al. Candidate genes for COPD in two large data sets. Eur Respir J 2011;37(2):255-63
96. Takasaka N, Araya J, Hara H, et al. Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence. J Immunol 2014;192(3):958-68
97. Barrero CA, Perez-Leal O, Aksoy M, et al. Histone 3.3 participates in a selfsustaining cascade of apoptosis that contributes to the progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188(6):673-83
98. Sundar IK, Nevid MZ, Friedman AE, Rahman I. Cigarette smoke induces distinct histone modifications in lung cells: Implications for the pathogenesis of COPD and lung cancer. J Proteome Res 2014;13(2):982-96
99. Hussain M, Rao M, Humphries AE, et al. Tobacco smoke induces polycombmediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 2009;69(8):3570-8
100. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373(9678):1905-17
101. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131(3):636-45
102. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200(5):689-95 (Pubitemid 39258317
103. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182(7):897-904
104. Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the antiinflammatory effects of steroids during exacerbations of COPD. Thorax 2009;64(5):424-9
105. Ford PA, Durham AL, Russell RE, et al. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010;137(6):1338-44
106. Mercado N, To Y, Ito K, Barnes PJ. Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-delta. J Pharmacol Exp Ther 2011;337(2):465-70
107. Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013;169(5):1024-34
108. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the antiinflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41(1):40-59
109. Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 2008;39(3):312-23
110. Suzuki M, Betsuyaku T, Ito Y, et al. Curcumin attenuates elastase-And cigarette smoke-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol 2009;296(4):L614-23
111. Mercado N, Thimmulappa R, Thomas CM, et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun 2011;406(2):292-8
112. Guan SP, Tee W, Ng DS, et al. Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. Br J Pharmacol 2013;168(7):1707-18
113. Kumar V, Kumar S, Hassan M, et al. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J Med Chem 2011;54(12):4147-59
114. Hwang TL, Leu YL, Kao SH, et al. Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway. Free Radic Biol Med 2006;41(9):1433-41
115. Sinclair DA, Guarente L. Small-molecule allosteric activators of sirtuins. Annu Rev Pharmacol Toxicol 2014;54:363-80
116. Kode A, Rajendrasozhan S, Caito S, et al. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008;294(3):L478-88
117. Knobloch J, Wahl C, Feldmann M, et al. Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic Acid in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 2014;114(2):202-9
118. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010;468(7327):1119-23
119. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 2012;109(47):19408-13
120. Shimamura T, Chen Z, Soucheray M, et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res 2013;19(22):6183-92
121. Okazaki Y, Furuno M, Kasukawa T, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 2002;420(6915):563-73 (Pubitemid 35477049
122. Amaral PP, Mattick JS. Noncoding RNA in development. Mamm Genome 2008;19(7-8):454-92
123. Mariner PD, Walters RD, Espinoza CA, et al. Human Alu RNA is a modular transacting repressor of mRNA transcription during heat shock. Mol Cell 2008;29(4):499-509 (Pubitemid 351282533
124. Moazed D. Small RNAs in transcriptional gene silencing and genome defence. Nature 2009;457(7228):413-20
125. Castel SE, Martienssen RA. RNA interference in the nucleus: Roles for small RNAs in transcription, epigenetics and beyond. Nat Rev Genet 2013;14(2):100-12
126. Ambros V. The functions of animal microRNAs. Nature 2004;431(7006):350-5 (Pubitemid 39265675
127. Pillai RS, Bhattacharyya SN, Artus CG, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 2005;309(5740):1573-6 (Pubitemid 41266485
128. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNA blocks protein production on actively translating polyribosomes. Nat Struct Mol Biol 2006;13(12):1108-14 (Pubitemid 44885922
129. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006;21(4):533-42 (Pubitemid 43228008
130. Oglesby IK, McElvaney NG, Greene CM. MicroRNAs in inflammatory lung disease-master regulators or target practice? Respir Res 2010;11:148
131. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: The fine-Tuners of Toll-like receptor signalling. Nat Rev Immunol 2011;11(3):163-75
132. Ezzie ME, Crawford M, Cho JH, et al. Gene expression networks in COPD: MicroRNA and mRNA regulation. Thorax 2012;67(2):122-31
133. Van Pottelberge GR, Mestdagh P, Bracke KR, et al. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183(7):898-906
134. De Flora S, Balansky R, D'Agostini F, et al. Smoke-induced microRNA and related proteome alterations. Modulation by chemopreventive agents. Int J Cancer 2012;131(12):2763-73
135. Izzotti A, Calin GA, Steele VE, et al. Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. FASEB J 2009;23(9):3243-50
136. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361(27):2599-608
137. Graff JW, Powers LS, Dickson AM, et al. Cigarette smoking decreases global microRNA expression in human alveolar macrophages. PLoS One 2012;7(8):e44066
138. Christenson SA, Brandsma CA, Campbell JD, et al. miR-638 regulates gene expression networks associated with emphysematous lung destruction. Genome Med 2013;5(12):114
139. Leidinger P, Keller A, Borries A, et al. Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung cancer 2011;74(1):41-7
140. Akbas F, Coskunpinar E, Aynaci E, et al. Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Exp Lung Res 2012;38(6):286-94
141. Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One 2013;8(1):e54596
142. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101(9):2999-3004 (Pubitemid 38327724
143. Davalos V, Moutinho C, Villanueva A, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012;31(16):2062-74
144. Basma H, Gunji Y, Iwasawa S, et al. Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells. Am J Physiol Lung Cell Mol Physiol 2014;306(6):L552-65
145. Zhou Y, Kim J, Yuan X, Braun T. Epigenetic modifications of stem cells: A paradigm for the control of cardiac progenitor cells. Circ Res 2011;109(9):1067-81
146. Paschalaki KE, Starke RD, Hu Y, et al. Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem Cells 2013;31(12):2813-26
147. Hoffmann G, Breitenbuecher F, Schuler M, Ehrenhofer-Murray AE.A novel SIRT2 inhibitor with p53-dependent pro-Apoptotic activity in non-small-cell lung cancer. J Biol Chem 2014;289(8):5208-16
148. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: Overview and perspectives. Future Med Chem 2012;4(11):1439-60